Record mula sa primary source
Decision-gradeTopline na resulta
Opus Genetics: 3-buwang topline data ng OPGx-BEST1 Phase 1/2 Cohort 1
Low-dose Cohort 1 data show 75% of evaluable patients met the FDA-aligned microperimetry endpoint and 80% had structural improvement. Cohort 2 is over-enrolled; 6-month Cohort 1 and 3-month Cohort 2 data are now expected in Q2 2027, with pivotal trial dosing slated to begin in 2027.
Mahahalagang fact
- Na-file
- Set 11, 2026, 11:48 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
IRDOpus Genetics- Asset
- OPGx-BEST1
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Dosis sa Grupo 1
- 1.5 x 10^9 vg/mata
- Dosis sa Grupo 2
- 4.5 x 10^9 vg/mata
- Pagbuti ng BCVA
- 3/5 na kalahok
- Paunang resulta ng Grupo 2
- Q2 2027
- Pagpapatala sa Grupo 2
- 8 kalahok
- Pagbuti sa istruktura
- 4/5 na kalahok
- Nakumpletong dosing sa Grupo 2
- Q4 2026
- Pagbuti sa microperimetry
- 3/4 na kalahok
Sipi mula sa source
EX-99.1 2 ef20081922_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to our continued clinical development, clinical results, preclini
Higit pa tungkol sa asset na ito
Kapansin-pansin
Ene 12, 2026
02:00 PM
IRDOpus GeneticsOpus Genetics: Inaasahan ang paunang datos ng OPGx-BEST1 Phase 1/2 sa Q1 2026